EUVIMEDEUVIMED entdecken
Crossref

Regulatory Frameworks for Drug Approval and Clinical Trials in Emerging Markets

Mr. Omkareshwar Pathak, Md Irfanul Haque, Shruti Rathore, Nainsi Agrawal

International Journal of Drug Delivery Technology · 23.04.2026 · 16 (17s)

DOI: 10.25258/ijddt.16.17s.46 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 23.04.2026. Verfasst von Mr. Omkareshwar Pathak und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

China, India, Brazil, South Africa, and members of the Association of Southeast Asian Nations (ASEAN) are all emerging pharmaceutical markets that in total cover more than 60% of the global population, and an ever-growing portion of clinical trial activity. These markets are very heterogeneous in terms of approval pathways, regulations to monitor clinical trials, and instead adherence to International Council for Harmonisation (ICH) standards, despite rapid increased regulation modernisation. Such disintegration provides obstacles to access to patients in time and exaggerates the development of drugs. Hypotheses: The foundations of this study included (i) to systematically compare the regulatory systems in eight emerging markets of licensing a drug and authorizing clinical trials related to them and (ii) quantify inter-country differences in median approval times, the use of expedited-regulatory paths, and the authorization of clinical trials (volumes). (iii) to test the maturity and efficacy of regional and international harmonization efforts.

Methods

A mixed-methods design was used which incorporated approaches of structural regulatory mapping against 14 preset indicators of governance and quantitative extraction of approval and trial- requesting data of national regulatory implementing agencies databases, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP) in the period of 2018-2024. The accuracy of data was verified according to peerreviewed sources and official reports by agencies.

Findings

Median times to approve new drugs were largely 10 months (China, priority pathway) to greater than 24 months (several jurisdictions in Africa). In 2024, it began 10,701 trials in China which were 61% of the total AsiaPacific trial activity, with the number of trials started increasing three times in India by 1710 in 2024 compared to 741 in 2014 and 10 commencing trials a day in 2014. The use of expedited pathways was quite different, with 39.1 percent of China approvals in 2024 of the expedited pathways (priority or conditional), and expedited mechanisms in sub-Saharan Africa predominantly undeveloped. Oncology approvals under Project ORBIS and similar collaborative review programs in Brazil were estimated to take 4-6 months to approve compared to single ANVISA review.

Conclusions

New markets have achieved considerable regulatory advancement, but there are still considerable differences. Further development of ICH alignment, digital submission and work-sharing schemes will be needed to decimate the access disparity bridging developed and arising pharmaceutical markets.

Zitieren

APA

Pathak, M. O., Haque, M. I., Rathore, S., & Agrawal, N. (2026). Regulatory Frameworks for Drug Approval and Clinical Trials in Emerging Markets. International Journal of Drug Delivery Technology, 16(17s). https://doi.org/10.25258/ijddt.16.17s.46

Vancouver

Pathak MO, Haque MI, Rathore S, Agrawal N. Regulatory Frameworks for Drug Approval and Clinical Trials in Emerging Markets. International Journal of Drug Delivery Technology. 2026;16(17s). doi:10.25258/ijddt.16.17s.46

BibTeX
@article{Pathak2026,
  author = {Pathak, Mr. Omkareshwar and Haque, Md Irfanul and Rathore, Shruti and Agrawal, Nainsi},
  title = {Regulatory Frameworks for Drug Approval and Clinical Trials in Emerging Markets},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {17s},
  doi = {10.25258/ijddt.16.17s.46}
}
Kostenlos starten →